front

SBiocon

COMPATIBILITY AND STABILITY Before Reconstitution. The dry powder should be stored at a temperature below 25°C. Reconstituted Solutions of MUCELUM[®] range from colories to yellow. Variations of color within this range do not affect the potency of the product.

Allect the potenty of the product. **Visis** IMICELUM⁴, as supplied in single use vials and reconstituted with the following diluents (see PREPARATION OF SOLUTION), maintains satisfactory potency for 4 hours at room temperature or for 24 hours under refiregration (5°C). See Statistic Charlos in the total on the forceen. See Aller Statistic Charles and Statistical International Sectors and 0.5% Social Charles International Sectors and 0.5% Social Charles Internation Sectors englection with 0.15% potassium chloride solution Mannitol 5% and 10%

IMICELUM[®] should not be mixed with or physically added to other antibiotics. However, IMICELUM[®] may be administered concomitantly with other antibiotics, such as aminoplycosides

HOW SUPPLIED IMICELUM[®] is supplied as a sterile powder mixture in single dose vial.

Storage: Store protected from moisture. Store below 25° C and protect from light. Keep out of reach of children.

Shelf Life: Please refer carton/label.

Marketed by: Biocon Biologics India Limited

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Imipenem and Cilastatin Injection IP

ℑIMICELUM[®]


TABLE II: REDUCED INTRAVENOUS DOSAGE OF IMICELUM® IN ADULT PATIENTS WITH IMPAIRED RENAL FUNCTION AND/OR BODYWEIGHT - 270 g COMPARIBUTY AND STABILITY

2.0 g/day And Body Weight

271 41-70 21-40 6-20 2.71 41-70 21-40 6-20 2.71 41-70 21-40 6-20

- 250
 125
 250
 125
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250
 250</th
- 125 125 125 125 250 250 250 250 250 250 250 250 250
- qish qish qish qizh qish qish qizh qizh qizh qish qish qizh 25 125 125 250 125 125 125 250 250 250 250
- qdb
 qdb
 q12b
 q12b
 qdb
 qdb
 qdb
 q12b
 q12b
 qdb
 q12b
 q2b
 q12b
 q12b</
- 30 q8h q8h q12h q12h q6h q8h q8h q12h q8h q12h q8h q12h

TABLE III REDUCED INTRAVENOUS DOSAGE OF IMICELUM® IN ADULT PATIENTS WITH IMPAIRED RENAL FUNCTION AND/OR BODY WEIGHT <70 kg If TOTAL DAILY DOSE from TABLE I is: 3.0 g/day 4.0 g/day And Body Weight (kg) [s: d creatinine clearance and creatinine clearance (mL/min/1.73 m³) is:



q8h q8h q8h q12h q8h q6h q8h q12h

dialysis. Hemodialysis When treating patients with creatinine clearances of < 5 When treating patients with creatinine clearances of < 5 When treating patients with creatinine clearances of for patients with creatinine clearances of for patients with creatinine clearances of function and/or Body Weight <7 dk kg) Both imperient and clastatin are cleared from the circulation during hemodialysis. The patient should receive MICEULW after hemodialysis and at 12 hour intervals timed from the end of that hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored, for patients on hemodialysis patients, especially those with background CNS disease, should be carefully monitored. For patients on hemodialysis patients, especially those with background Event to utweighs the potential risk disecures. Medistric Patients benefit downers to preserve the preserve of the recommended dose for non-CNS infections is 15 to 25 mg/kg/dose administered every six hours. Based on studies in adults, the maximum daily dose for treatment of infections with fully moderately susceptible organism (primarily some strains of P aeruginos) is 4.0 g/day. Higher dose (so the primarily some strains of P aeruginos) is 4.0 g/day. Higher dose (so the primarily some strains of P aeruginos) is 4.0 g/day. Higher dose (so the primarily some strains of P aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the primarily some strains of P. aeruginos) is 4.0 g/day. Higher dose (so the point) for the point of the

इमिसेलम

Patients with creatinine clearance <5 mL/min/1.73 m² should not receive IMICELUM⁴ unless hemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of IMICELUM^{*} for patients undergoing peritoneal dialysis.

For pediatric patients ≤ 3 months of age (weighing ≥1500 gm), the following dosage schedule is recommended for non-CNS infections: <1 wk of age 1-4 wks of age 4 wks-3 mos. of age

25 mg/kg every 12 hrs 25 mg/kg every 8 hrs 25 mg/kg every 6 hrs. Biocon House, Semicon Park Electronics City, Phase - II, Bengaluru - 560 100, India. Doses less than or equal to 500 mg should be given by intravenous infusion over 15 to 30 minutes. Doses greater than 500 mg should be given by intravenous infusion over 40 to 60 minutes. ® - Registered trademark Leaflet revised on August 2019 To report adverse events and/or product complaints visit our website www.biocon.com or call toll free No: 1800 102 9465 or e-mail us at drugsafety@biocon.com

IMICELUM[®] is not recommended in pediatric patients with CNS infections because of the risk of seizures. IMICELUM[®] is not recommended in pediatric patients <30 kg with impaired renal function, as no data are available.

PREPARATION OF SOLUTION Vials

Vials Contents of the vials must be suspended and transferred to 100 mL of an appropriate infusion solution. A suggested procedure is to add approximately 10 mL from the appropriate infusion solution (see list of diluents under COMPATIBILITY AND STABILITY) to the vial. Shake well and transfer the resulting suspension to the infusion solution container.

Benzyl alcohol as a preservative has been associated with toxicity in neonates. While toxicity has not been demonstrated in pediatric patients greater than three months of age, pediatric patients in this age range may also be at risk for benzyl alcohol toxicity. Therefore, diluents containing benzyl alcohol should not be used when IMICELUM[®] is constituted for administration to pediatric patients in this age range.

Δ

Patients with creatinine clearances of 6 to 20 mL/min/1.73 m² should be treated with IMICELUM * 125 mg or 250 mg every

CAUTION: THE SUSPENSION IS NOT FOR DIRECT INFUSION. Repeat with an additional 10 mL of infusion solution to ensu

back

Biocon

only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Imipenem and Cilastatin Injection IP

IMICELUM

Composition: Each Vial Contains: Imipenem IP (sterile) Eq. to Anhydrous Imipenem Cilastatin Sodium IP (sterile)

Liidstatin Sodium IP (sterile) 500 mg Sodium Bicarbonate IP (Sterile) q.s. (as Buffer)

(as Suirer) **DESCRIPTION** IMICELUM* (imigenem and Cilastatin Injection IP) is a sterile formulation of Imigenem (a thienamycin antibiotic) and Cilastatin Sodium (the inhibitor of the renal dipertidase, delydropertidase), with sodium bicarbonate added as a buffer. IMICELUM* is a potent broad spectrum antibacterial agent for intravenous administration. Questionance. **Microbiology** The bactericidal activity of imipenem results from the inhibition of cell wall synchesis. Its greatest affinity is for penicillin binding proteins (PBPs) 1A, 1B, 2, 4, 5 and 6 of *Escherichia coli*, and 1A, 1B, 2, 4 and 5 of *Resultanonas aeruginas*. The lefthal effect is related to binding to PBP 2 and PBP 1B.

500 mg

Interperent (N-formimidoylthienamycin monohydrate) is a crystalline derivative of thienamycin, which is produced by Streptomyces cattlyea, its chemical name is (S.R.65)-31(2-(formimidoylamino)ethylthio]-6 (R)-1-hydroxyethyl7-roxo-1-azabicycl03 2.0 (Diept-2-ene-2-adroxylic acid monohydrate ti is an off white, nonhygroscopic crystalline compound with a molecular weight of 317.37 (1: sparingly soluble in water and silghtly soluble in methanol. Its empirical formula is C.H.W.Q.S.H.O.

related uplinuing upper 2 and reprint. Imigenem has a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases produced by gram-negative and gram-positive bacteria. It is a potent inhibitor of beta-lactamases from certain gram-negative bacteria which are inherently resistant to most beta-lactam antibiotics, e.g., /Seudomonas aeruginosa, Serratia spp., and Enterobacterspp. C.,H.,N.Q.S.H.O. Clastatin Sodium is the sodium salt of a derivatized hepten acid. Its chemical name is sodium (2)-71((R)-2-amino-carboxyethy)(Hio)-2-((3)-2, dimethy(C)copropan carboxamido)-2-heptenoate. It is an off-white to yellowin white, hygroscopic, amorphous compound with a molecu weight of 380.43, its very soluble in water and in methanol. empirical formulas C.,H.,N.Q.SNa Interpent has in vitro activity against a wide range of gram-positive and gram-negative organisms. Impenem has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections treated with the intervenous formulation of impenem-cilastatin sodium as described in the INDICATIONS AND USAGE section.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY Adults and the standard st

dose. The plasma half-life of each component is approximately 1 hour. The binding of imigenem to human serum proteins is approximately 20% and that of clastatin is approximately 40%. An the unrew yold that of clastatin is approximately 40% of the unrew yold that of clastatin is approximately 40%. In the unrew yold that of clastatin is approximately 40% excess of 10 yolm. Can be maintained for up to 8 hours with Imipenem and Clastatin at the 500 mg dose. Approximately 70% of the clastatin sodium dose is recovered in the unrew within 10 hours of administration of Imipenem and Clastatin.

No accumulation of imipenem/cilastatin in plasma or urine is observed with regimens administered as frequently as every 6 hours in patients with normal renal function.

nours in patients with normal renal function. In healthy delay volunteers (56 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of inipement 500 mg and cilastatin 500 mg administered intravenously over 20 minutes are consistent with those expected in subjects with slight renal impairment for which no dosage alteration is considered necessary. The mean plasma half-lives of impenem and cilastatin are 91 ± 7.0 minutes and Gram-positive aerobes: Bacillus spp. Listeria monocytogenes, Nocardia spp., Staphylococcus saprophyticus, Group C streptococci Group G streptococci, Viridans group streptococci Gram-negative aerobes: Aeromonas hvdrophila, Alcaligenes spp., Capnocytophaga

spp., Haemophilus ducreyi, Neisseria gonorrhoeae including penicilinase-producing strains, Pasteurella spp. Providencia stuartii 69 ± 15 minutes, respectively. Multiple dosing has no effect on the pharmacokinetics of either imigenem or cilastatin, and no accumulation of imipenem/cilastatin is observed.

इमिसेलम

sodium as described in the INDICATIONS AND USACE section. Gram-positive aerobes: Enterococcus facealis (formerly S. facealis) (NOTE: Imperemt is Inactive in vitro against Enteronoccus including penicillinase-producing strains, Staphylococcus including penicillinase-producing strains, Staphylococcus epidermidis including penicillinase-producing strains (NOTE: Methicillin-resistant staphylococci should be reported as streigenecci, Streptococcus apleumonia, Streptococcus personaneutina agabaci

groupies Gram-negative aerobes: Acinetobacter, "pp.," Child segnals, Heernophilus influenza, Heernophilus parainfluenza, Klebsiella sp., Morganella morgani, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, Serrata sp., including S. marcescens, (NOTE: Imipenem is inactive in vitro against Xanthomonas (Pseudomonas) maltophila autosome starias of R cepaca)

Gram-positive anaerobes: Bifidobacterium spp., Clastridium spp., Eubacterium spp., Peptococcus spp., Peptostreptococcus spp. Propionibacterium

The following *in vitro* data are available, but their clinical significance is unknown.

1

इमिसेलम

pain, glossitis, tongue papillar hypertrophy, staining of the teeth addor tongue, heartburn, phanyngel pain, increased salivation; "Hematologic - panychopenia, hone marrow depression, thrombocytopenia, neutropenia, leukopenia, hemolytic anemia; **CNS** -encephalopathy, tremor, confusion, myocionus, paresthesia, vertigo, headache, psychic disturbances including hallucinations; **Special Sense**-hearing loss, tinnitus, taste perversion, **Respiratory** - chest discomfort, dyspnea, hyperventiation, thoracci spine pain; **Cardiovascular** - palpitations, tachycardia, **Skin** - Stevens-binson synchrome, toxic opularmal netrophys, evythemes hyperhidrosis, skin texture changes, candidiais, puritus vulvae; **Eody sa vhole**, polyarthajdia, asthenia/weaknes, drug fever; **Renal** - acute renal fallure, oliguria/anuria, polyura, unite discoloration.

Hepatic: Increased ALT (SGPT), AST (SGOT), alkaline phosphatase, bilirubin, and LDH

Hematology: Increased eosinophils, positive Coombs test, increased WBC, increased platelets, decreased hemoglobin and hematocrit, agranulocytosis, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils

Electrolytes: Decreased serum sodium, increased potassium, increased chloride

Urinalysis: Presence of urine protein, urine red blood cells, urine white blood cells, urine casts, urine bilirubin, and urine

OVERUGABLE In the case of overdosage discontinue IMICELUM®, treat symptomatically, and institute supportive measures as required. Imigenem-cilastatin sodium is hemodialyzable. However, usefulness of this procedure in the overdosage setting is questionable.

CONTRAINDICATION IMICELUM® is contraindicated in patients who have shown hypersensitivity to any component of this product

DOSAGE ANU ADMINISTRATION Adults The dosage recommendations for IMICELUM[®] represent the quantity of impenem to be administered. An equivalent amount of classian is also present in the solution. Each 125 or administrating over 20 to 30 minutes. Each 750 mg or 1000 mg dose should be infused over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed.

may be slowed. The total daily dosage for IMICELUM^{*} should be based on the type or severity of infection and given in equally divided doses based on consideration of degree of susceptibility of the pathogen(s), renal function, and body weight. Adult patients with impared renal function, as judged by creatinnic eclearance <70 m/Jmin/1.73 m², require adjustment of dosage as described in the succeeding section of these guidelines.

Intravenous Dosage schedule for adults with normal renal function and body.Weight > 70kg. Doses cited in below Table I are based on a patient with normal

3

without regard to drug uring clinical trials or reported

uria, urine discoloration

Adverse Laboratory Changes Adverse laboratory changes v relationship that were reported dur since the drug was marketed were:

Renal: Increased BUN_creatinine

DOSAGE AND ADMINISTRATION

OVERDOSAGE

Gram-negative anaerobes: Bacteroides spp., including B. fragilis, Fusobacterium spp.

spp

accumulation or imperentification to USBENED. Imperem, when administered alone, is metabolized in the kidneys by dehydropeptidase I resulting in relatively low levels in urine. Cilastatin sodium, an inhibitor of this eazyme, effectively prevents renal metabolism of imipenem so that when imipenem and clastatin sodium are given concomitantly, fully adequate antibacterial levels of imipenem are achieved in the urine. Imipenem-cilastatin sodium is hemodialyzable. However, usefulness of this procedure in the overdosage setting is questionable.

Gram-negative anaerobes: Prevotella bivia, Prevotella disi-In vitro tests show imipenem to act synergistically with aminoplycoside antibiotics against some isolates of

UM" is indicated for the treatment of serious infections I by susceptible strains of the designated microorganisms in iditions listed below: INDICATIONS AND USAGE

SBiocon

(1)

(2)

(4)

(5)

(6)

(7)

Lower respiratory tract infections: Staphylococcus aureus (penicillinase-producing strains), Acinetobacter species, Interobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae^{*}, Klebsiella species, Serratia oaraintiuen marcescens

unarcesterb. Urinary tract infections (complicated and uncomplicated): Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Morganella morgani, Proteus vulgaris^{*}, Providencia rettgen^{*}, Pseudomonas aeruginosa (3)

aeruginosa Intra-abdominal infections: Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia ocli, Klebsiella species, Morganella morgani, Proteus species, Pseudomonas aeruginosa, Bridobacterium species, Clostridium species, Seateroides species including B. fragilis, Fusobacterium species Cumencloaris infection:

species **Gynecologicinfections:** Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococc), Enterobacter species, Escherichia coli, dididobacterium, species, Peptococcus species, Peptosterptococcus species, Peptococcus species, Bacteroides species in Projonibacterium species, Bacteroides species in the streption of the st

Bacterial septicemia: Enterococcus faecalis, Staphylococcus aureus (pencillnas-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginoa, Seratia species, Bacteroides species including B. fragilis

Bone and joint infections: Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter species, Pseudomonas consistence

renal function and a body weight of 70 kg. These doses should be used for a patient with a creatinine clearance of 271 mL/mn/1.73 m² and a body weight of 270 kg. A reduction in dose must be made for a patient with a creatinine clearance of 570 mL/mn/1.73 m² and dor a body weight of 20 kg.

Desage regimes in column A of Table I are sommended for infections caused by fully susceptible organisms which represent the majority of pathogonic species. Docage regimes in column 8 of Table I are recommended for infections cause by organisms with moderate susceptibility to imipenem, primarily some strains of *P aeruginosa*.

TABLE I INTRAVENOUS DOSAGE SCHEDULE FOR ADULTS WITH NORMAL RENAL FUNCTION AND BODY WEIGHT 270 kg

A Fully susceptible proanisms including

gram-positive and gram-negative aerobes and anaembes

250 mg q6h L DAILY DOSE = 1.0g)

500 mg q8h TOTAL DAILY DOSE = 1.5q)

500 mg q6h TOTAL DAILY DOSE = 2.0g)

250 mg q6h OTAL DAILY DOSE = 1.00)

500 mg q6h OTAL DAILY DOSE = 2.0g)

Due to the high antimicrobial activity of IMICELUM[®], it is recommended that the maximum total daily docage not exceed 50 mg/kg/day or 40 g/day, whichever is lower. There is however, patients over theve years of age which cyclic fibrosis and normal renal function have been treated with NMICELUM[®] at docse up to 90 mg/kg/day in divided doses, not exceeding 4.0 g/day.

Reduced Intravenous Schedule for Adults with Impaired Renal Function and/or Body Weight <70 kg, Patients with creatine dearance of 570 mL/min/1, 73 m² and/or body weight less than 70 kg require dosage reduction of IMICELUM[®] as indicated in the table below.

To determine the dose for adults with impaired renal function and/or reduced body weight: 1. Choose a total daily dose from Table I based on infection

characteristics. 2.a) If the total daily dose is 1.0 g, 1.5 g, or 2.0 g, use the appropriate subsection of Table II and continue with step 3.

 b) If the total daily dose is 3.0 g or 4.0 g, use the appropriate subsection of Table III and continue with step 3. Subsection or lable in and continue with step 3. 3. From Table in or III: a) Select the body weight on the far left which is closest to the patient's body weight (kg). b) Select the patient's creatinine clearance category. c) Where the row and column intersect is the reduced

or 500 mg q6h DTAL DAILY DOSE = 2.0q

oderate

Severe, life threatening only

es below

dosage regimen.

aeruginosa Skin and skin structure infections: Enterococcus faecalis, Staphylococcus aureus epidemidia, Acinetobacter species, Citrobacter species, Enterobacter species, Scherichia coli, Klebiskia species, Morganela morgani, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginos, Serraita species,

SBiocon

B Moderately susceptible organisms, primarily some strains of *P. eer* up in our

500 mg q6h TOTAL DAILY DOSE = 2.0

500 mg q6h (TOTAL DAILY DOSE = 2.0g)

or 1 g q8h (TOTAL DAILY DOSE = 3.0c

1 g q8h (TOTAL DAILY DOSE = 3.0g)

or 1 g q6h (TOTAL DAILY DDSE = 4.0g)

250 mg q6h (TOTAL DAILY DOSE = 1.0g)

500 mg q6h (TOTAL DAILY DOSE = 2.0

only of a Registered Medical Practitioner or a Hospital or a Laboratory Imipenem and Cilastatin Injection IP

ℑIMICELUM[®]

30

coccus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species

- Endocarditis: Staphylococcus aureus (penicillinase-producing strains)
- Staphylococcus aureus upeneumene Polymicrobic infections: MICEUIMM is indicated for polymicrobic infections including those in which S. progemoraize (pneumonia, septicemia). S. progenes (skin and skin structure), or onopenicillinas-producing. S. aureus is one of the causative organisms: a tousially treated with narrower spectrum antibiotics, such as pencillin G.

spectrum antibiotics, such as penicillin G. IMCELLW[®] is not indicated in patients with meningitis because safety and efficacy have not been established. Because of its broad spectrum of bactericial activity against gram-positive and gram-negative serobic and anaerobic bacteria, IMCELLW[®] is useful for the treatment of mixed infections and as presumptive therapy prior to the identification of the causative organisms. Although clinical improvement has been observed in patients with cysic fibrosis, chronic pulmoary disease, and lower repriratory tract infections caused by *Pseudomosal earuginosa*, bacterial eradication may not necessanily be achieved.

Infections resistant to other antibiotics, for example, cephalosporins, penicillin, and aminoglycosides, have been shown to respond to treatment with IMICELUM®

To reduce the development of drug-resistant bacteria and maintain the effectiveness of IMICELUM[®] and other antibacterial drugs, IMICELUM[®] should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

* Efficacy for this organism in this organ system was studied in fewer than 10 infections.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

of The app. WARNINGS SERIOUS AND OCCASIONALLY FATAL HYPERSENSITI-VITY (ANAPHYLACTIC) REACTIONS HAR WE BEEN REPORTED IN PATIENTS RECEIVING THERAPY WITH BETA-LACTAMINS. THESE REACTIONS ARE MORE APT TO OCCUR IN PERSONS WITH A HISTORY OF DETAIL OF THE DECOMPOSITION OF THE DECOMPOSITION OF DECOMPOSITION OF THE DECOMPOSITI

TO OCCUR IN PERSONS WITH A HISTORY OF SEMSITIVITY MULTIPEALLERGENS. THERE HAVE BEEN REPORTS OF PATENTS WITH A HISTORY OF PENICILIN PHPERSENSITIVITY WHO HAVE EXPENIENCED SEVERE HYPERSENSITIVITY LACTAM. BEFORE INITIATING THERAPY WITH IMICELUM", CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILINS, CEPHALOSPORINS, OTHER BETA-LACTAMS, AND OTHER ALLERGENS. IF AN ALLERGICREACTION OCCURS, MICELUM"SHOULD BE DISCONTINUED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITHS, AND ARWAY MANAGEMENT, INCLUDING NUTURATION, MAY ALSO BE ADMINISTERED AS INDICATED

Seizure Potential Seizures and other CNS adverse experiences, such as confusional states and mycoline activity, have been reported during treatment with Impenem and Cilastatin. Case reports in the literature have shown that co-administration of carbapenems, including impenem, to patients receiving valioric acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Increasing the dose of valproic acid or divalproice socionomilant use of impenem and valproic acid/divalproice socionomilant use of impenem and valproic acid/divalproice socionomilant use of impenem and valproic acid/divalproice socionomilant use of impenemental on an environment interaction, patients whose seizures are well controlled on valproic acid or collastatin is necessary, supelemental and charbanet intercions in theorem and the company theorem and valproic acid or collastatin selections. The second of the considered to the trainet intercions in the considered.

इमिसेलम

Clostrollard and the approximation of the approxima

Indicated. **PRECAUTIONS General** CINS adverse experiences such as confusional states, myoclonic activity, and seizures have been reported during treatment with impenem and Clastatin, especially when recommended dosages were exceeded. These experiences have occurred most commonly in patients with CNS discords (e.g., han function. However, there have been reports of CNS adverse experiences in patients who had no recognized or documented underlying CNS disorder or compromised renal function. Memor incommander dross were exceeded, adult batients

experiences intraduents with intal horecognized of bocumented underlying CNA Sisordeer or componsised enal function. When recommended doses were exceeded, adult patients with creatinine clearances of 22 Dullmin/1.73 m, whether or not undergoing hemodalysis, had a higher risk of seizure activity than those without impainment of renal function. Data those without intradiction of the seizure activity than those without intradiction of the seizure activity than those without into the receive MRUE LUM⁴ muss hemodalysis is instituted within 48 hours. For patients on hemodalysis is instituted within 48 hours, for patients on hemodalysis is instituted within 48 hours. For patients on hemodalysis is instituted within 48 hours, separate evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken. Prescribing MRELEUM⁶ in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistantbacteria.

2

Information for Patients Patients should be counseled to inform their physician if they are taking valproic acid or divalprox sodium. Valproic acid concentrations in the blood may drop below the therapeutic range upon co-dministration with IMICELUM[®] If treatment with Internetial Articroniciant medication to a premain we or treat secures may be needed. Patients should be counseled that antibacterial drugs including IMICELUM[®] should only be used to treat secures may be needed. Patients should be too that although it is common to fee batter early in the course of the attributes or not control to the store of the skipping does or not completing the full course of the that although will control to be batter early in the course of the target, the medication should be taken exactly as directed. Skipping does or not completing the full course of the rapy, the medication should be taken exactly as directed and the target of the target of the target of the resistance and will not be treatable by IMICELUM[®] or other antibacterial drugs in the future.

anituacterial orugian interioutie. Diarrhea is a common problem caused by antibiotics, which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and Bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients shoule contact their physician as soon as possible.

Laboratory Tests While IMICELIMM possesses the characteristic low toxicity of the beta-lactar group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.

Drug Interactions Generalized seizures have been reported in patients who received ganciclovir and imigenem. These drugs should not be used concomitantly unless the potential benefits outweigh the risks.

TINS. Since concomitant administration of Imipenem and Cilastatin and probenecid results in only minimal increases in plasma gives for imperem and plasma half-filer, it is not recommended that probenecid be given with imipenem and Cilastatin. Imipenem and Cilastatin should not be mixed with or physically added to other antibiotics. However Imipenem and Cilastatin may be administered concomitantly with other antibiotics, such as amimoglycosides.

Case reports in the literature have sho administration of carbapenems, including Administration of carbapenems, including imjenem, to patients receiving valproic acid or divalprocessodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough sezures. Although the mechanism of this interaction is unknown, data from *in intro* and animal studies valproic acid's glucuromie metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid.

acid. Carcinogenesis, Mutagenesis, Impairment of Fertility Long term studies in animals have not been performed to evaluate carcinogenic potential of imipenem-cilastatin. Genetic toxicity studies were performed in a variety of bacterial and mammalian tests in vivo and in vitro. The tests used vere: V79 mammalian cell mutagenesis assay (imipenem-cilastatin sodium alone and imipenem alone), Ames test (icilastatin sodium alone and imipenem alone), unscheduled DNA softogenetics test (imipenem-cilastatin sodium). None of these tests showed any evidence of genetic alterations.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Imipenem and Cilastatin Injection IP

ℑIMICELUM[®]

Reproductive tests in male and female rats were performed with imigenem-cliastatin sodium at intravenous doses up to 80 mg/kg/dgv and at a subcutaneous dose of 320 mg/kg/dgv, approximately equal to the highest recommended human dose of the intravenus formulation (on a mg/m body surface area basis). Slight decreases in live fetal body weight were restricted to the highest dosage level. No other adverse effects were observed on fertility, reproductive performance, fetal viability, growth or opstratal development of pups.

Pregnancy: Teratogenic Effects There are, however, no adequate and well-controlled studies in pregnant women. Impenem and Clastatin for Injection should be used during pregnancy only if the potential benefit justifies the potential is to the mother and fetus.

Nursing worters It is not known whether imipenem-cilastatin sodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Imipenem and Cilastatin for Injection is administered to a nursing woman.

Clastatin for injection is administered to a nursing woman. **Pediatric Use** Use of Imipenem and Clastatin for Injection in pediatric patients, neonates to 16 years of age, is supported by evidence from adequate and well-controlled studies. Imipenem and Clastatin for Injection is not recommended in pediatric patients with CNS infections because of the risk of seizures. Imipenem and Clastatin for Injection is not recommended in pediatric patients <30 kg with impaired renal function, as no data are available.

Geriatric Use No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

sensumy or some older individuals cannot be ruled out." This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in does selection, and it may be useful to monitor renal footagon king dosage adjustment is required based on age. necessary.

em and Cilastatin is generally well tolerated.

Influeeven infection - 0.1% Systemic Adverse Reactions The most frequently reported systemic adverse clinical reactions that were reported as possibly, probably, or definitely related to Impenem and Cilastatin were nausea (2.0%), hypotension (0.4%), seizures (0.4%), dazioness (0.3%), pruntus (0.3%), uriticaria (0.2%), sonnolence (0.2%).

Adverse systemic clinical reactions reported in less than 0.2% of the patients or reported are listed within each body system in order of decreasing severity: **Gastrointestinal** – pseudomembranous collitis (the onset of pseudomembranous collitis symptoms may occur during or after antibacterial treatment), hemorting clinics, hepatitis (including fulminant hepatitis), hepatic failure, jaundice, gastroenterits, abdominal

- 3.1% - 0.7% - 0.4% - 0.2% - 0.1%

Nursing Mothers

Geriatric Use

ADVERSE REACTIONS

Local Adverse Reactions Phlebitis/thrombophlebitis

rniebitis/thrombophlebitis Pain at the injection site Erythema at the injection site Vein induration

Infused vein infection